The numbers needed to treat for neurological disorders

Canadian Journal of Neurological Sciences

Volumn 32, Issue 4, 2005, Pages 440-449

  Bussière, Miguel ^a   Wiebe, Samuel ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BETA1A INTERFERON; CARBAMAZEPINE; CORTICOTROPIN; DIAZEPAM; DONEPEZIL; FLUMAZENIL; GABAPENTIN; GALANTAMINE; GINKGO BILOBA EXTRACT; GLATIRAMER; INTERFERON BETA SERINE; LAMOTRIGINE; MAGNESIUM SULFATE; MANNITOL; MENINGOCOCCUS VACCINE; METHYLPREDNISOLONE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; RIVASTIGMINE; STEROID; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

ALZHEIMER DISEASE; ARTICLE; BLOOD AUTOTRANSFUSION; CLINICAL PRACTICE; CLINICAL TRIAL; COCHRANE LIBRARY; DEMYELINATING DISEASE; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL EDUCATION; META ANALYSIS; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROSCIENCE; NEUROSURGERY; OPTIC NERVE DISEASE; OUTCOMES RESEARCH; POSTDURAL PUNCTURE HEADACHE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; VACCINATION;

EID: 29044433712     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S031716710000442X     Document Type: Article

References (90)

1. Bussiere M, Wiebe S. Measuring the benefit of therapies for neurological disorders. Can J Neurol Sci 2005; 32:419-424.
2. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
3. Wiffen P, Collins S, McQuay H, et al. Anticonvulsant drugs for acute and chronic pain (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Oxford: Update Software.
4. Wiebe S, Blume WT, Girvin JP, Eliasziw M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345:311-318.
5. Mehndiratta MM, Hughes RAC. Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
6. Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346:549-556.
7. Bernard SA, Gray TW, Buist MD et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002; 346:557-563.
8. Birks JS, Harvey R. Donepezil for dementia due to Alzheimer's disease (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
9. Olin J, Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
10. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's disease (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
11. Birks J, Grimley Evans J, Van Dongen M. Ginkgo Biloba for Cognitive Impairment and Dementia (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
12. Als-Nielsen B, Kjaergard LL, Gluud C. Benzodiazepine receptor antagonists for acute and chronic hepatic encephalopathy (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
13. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343:898-904.
14. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357:1576-1582.
15. CHAMPS Study Group. Interferon beta-1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 2001; 132:463-471.
16. Kaufman DI, Trobe JD, Eggenberger ER, Whitaker JN. Practice parameter: the role of corticosteroids in the management of acute monosymptomatic optic neuritis. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 54:2039-2044.
17. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000; 247:435-442.
18. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial Neurology 1997; 49:1404-1413.
19. Filippini G, Brusaferri F, Sibley WA, et al. Corticosteroids or ACTH for acute exacerbations in multiple sclerosis (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
20. Rice GPA, Incorvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
21. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003; 361:545-552.
22. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995; 45:1268-1276.
23. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998; 50:701-708.
24. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997; 278:144-151.
25. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. Gabapentin add-on for drug-resistant partial epilepsy (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
26. Ramaratnam S, Marson AG, Baker GA. Lamotrigine add-on for drug-resistant partial epilepsy (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Oxford: Update Software.
27. Chaisewikul R, Privitera MD, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
28. Castillo S, Schmidt DB, White S. Oxcarbazepine add-on for drug-resistant partial epilepsy (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
29. Pereira J, Marson AG, Hutton JL. Tiagabine add-on for drug-resistant partial epilepsy (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
30. Jette NJ, Marson AG, Hutton JL. Topiramate add-on for drug-resistant partial epilepsy (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
31. Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
32. Privitera MD, Welty TE, Ficker DM, Welge J. Vagus nerve stimulation for partial seizures (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
33. First Seizure Trial Group. Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. Neurology 1993; 54:478-483.
34. Wiebe S. An evidence based approach to the first unprovoked seizure. Can J Neurol Sci 2002; 29:120-124.
35. Duley L, Gülmezoglu AM, Henderson-Smart DJ. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
36. Duley L, Henderson-Smart D. Magnesium sulphate versus diazepam for eclampsia (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
37. Duley L, Henderson-Smart D. Magnesium sulphate versus phenytoin for eclampsia (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
38. Schierhout G, Roberts I. Anti-epileptic drugs for preventing seizures following acute traumatic brain injury (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
39. Roberts I, Schierhout G, Wakai A. Mannitol for acute traumatic brain injury (Cochrane Review). In: The Cochrane Library Issue 3, 2003, 2003. Oxford: Update Software.
40. Hancock E, Osborne J, Milner P. Treatment of infantile spasms (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
41. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 1991; 337:1175-1180.
42. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998; 280:1831-1836.
43. McQuay HJ, Tramer M, Nye BA, et al. A systematic review of antidepressants in neuropathic pain. Pain 1996; 68:217-227.
44. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specific low back pain (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
45. van Tulder MW, Scholten RJPM, Koes BW, Deyo RA. Non-steroidal anti-inflammatory drugs for low back pain (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
46. Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
47. McCrory DC, Gray RN. Oral sumatriptan for acute migraine (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
48. Sudlow C, Warlow C. Epidural blood patching for preventing and treating post-dural puncture headache (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
49. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998; 280:1837-1842.
50. de Gans J, van de BD. Dexamethasone in adults with bacterial meningitis. N Engl J Med 2002; 347:1549-1556.
51. Saunas R, Prasad K. Drugs for treating neurocysticercosis (tapeworm infection of the brain) (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
52. Whitley RJ, Alford CA, Hirsch MS, et al. Vidarabine versus acyclovir therapy in herpes simplex encephalitis. N Engl J Med 1986; 314:144-149.
53. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
54. Prasad K, Volmink J, Menon GR. Steroids for treating tuberculous meningitis (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
55. Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TRE. Benzodiazepines for neuroleptic-induced acute akathisia (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
56. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000; 342:1484-1491.
57. Clarke CE, Speller JM. Pergolide versus bromocriptine for levodopa-induced complications in Parkinson's disease (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
58. Clarke CE, Deane KHO. Ropinirole for levodopa-induced complications in Parkinson's disease (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
59. Clarke CE, Speller JM, Clarke JA. Pramipexole for levodopa-induced complications in Parkinson's disease (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
60. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
61. Verdugo RJ, Salinas RS, Castillo J, Cea JG. Surgical versus non-surgical treatment for carpal tunnel syndrome (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
62. Van Schaik IN, Winer JB, de Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculopathy (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
63. Raphaël JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
64. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 1992; 326:1123-1129.
65. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280:1485-1489.
66. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996; 78:1470-1476.
67. The Prophylactic Cranial Irradiation Overview Collaborative Group. Cranial irradiation for preventing brain metastases of small cell lung cancer in patients in complete remission (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
68. Rinkel GJE, Feigin VL, Algra A, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
69. Molyneux A, Kerr R, Stratton I, et al. International Subarachnoid Aneurysm Trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised trial. Lancet 2002; 360:1267-1274.
70. Wardlaw JM, del Zoppo G, Yamaguchi T. Thrombolysis for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
71. Sandercock P, Gubitz G, Foley P, Counsell C. Antiplatelet therapy for acute ischaemic stroke (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
72. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke (Cochrane Review). In: The Cochrane Library Issue 3, 2003. Oxford: Update Software.
73. Benavente O, Hart R, Koudstaal P, Laupacis A, McBride R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks (Cochrane Review). In: The Cochrane Library Issue 3, 2003. Oxford: Update Software.
74. Segal JB, McNamara RL, Miller MR, et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Oxford: Update Software.
75. Chambers BR, You RX, Donnan G. Carotid endarterectomy for asymptomatic carotid stenosis (Cochrane Review). In: The Cochrane Library Issue 3, 2003. Oxford: Update Software.
76. Perry HM, Jr., Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000; 284:465-471.
77. Koudstaal PJ. Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attacks (Cochrane Review). In: The Cochrane Library Issue 3, 2003. Oxford: Update Software.
78. Hankey GJ, Sudlow CLM, Dunbabin DW. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
79. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:331-337.
80. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1-13.
81. Gueyffier F, Boissel JP, Boutitie F, et al. Effect of antihypertensive treatment in patients having already suffered from stroke. Gathering the evidence. Stroke 1997; 28:2557-2562.
82. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033-1041.
83. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
84. Cina CS, Clase CM, Haynes RB. Carotid endarterectomy for symptomatic carotid stenosis (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
85. Hilton MPD. The Epley (canalith repositioning) manoeuvre for benign paroxysmal positional vertigo (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
86. Amaragiri SV, Lees TA. Elastic compression stockings for prevention of deep vein thrombosis (Cochrane Review). In: The Cochrane Library Issue 3, 2004. Oxford: Update Software.
87. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000; 54:1166-1175.
88. Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. BMJ 1999; 318:1548-51.
89. McAlister FA, Straus SE, Guyatt GH, Haynes RB. Users' guides to the medical literature: XX. Integrating research evidence with the care of the individual patient. Evidence-Based Medicine Working Group. JAMA 2000; 283:2829-2836.
90. Sinclair JC, Cook RJ, Guyatt GH, Pauker SG, Cook DJ. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol 2001; 54:253-262.